Results 241 to 250 of about 3,746,725 (298)

Evaluation of hyaluronic acid and type III procollagen peptide as predictors for treatment response to direct-acting antivirals. [PDF]

World J Virol
Abdelrazek MA, Elghwab AI, Tabll AA, Elsayed EH, El Behery M.   +4 more
europepmc   +1 more source

Prescribing direct-acting antivirals for hepatitis C treatment: a scoping review of factors that influence primary care providers. [PDF]

BMC Prim Care
Hallett J, Price T, Gray C, Rosenberg S, Lobo R, Crawford G.   +5 more
europepmc   +1 more source

Retraction: Outcomes of Direct-Acting Antivirals Versus Interferon-Based Therapy in Chronic Hepatitis C Infection. [PDF]

Cureus
Chowdhury R, Rashid W, Singh T, Rehman A, Daterdiwala NF, Mkosi V, Limbu B, Bukhari SA, Ramadhan A, Dabas MM, Shehryar A, Khan R.   +11 more
europepmc   +1 more source

Post-treatment life-trajectories among people who inject drugs who completed hepatitis C treatment with direct acting antivirals: A thematic analysis. [PDF]

Br J Health Psychol
Vojt G, Elliott L, Family H, Sharkey C, Stephens B, Hutchinson S, Hickman M, Dillon JF, Harris M, Flowers P.   +9 more
europepmc   +1 more source

Modulation of glucose metabolism and insulin resistance following hepatitis C virus clearance via direct-acting antivirals. [PDF]

Sci Rep
Jabeen S, Khan R, Alrashed MM, Ullah S, Nabi G, Ullah MI, Waqar AB, Attia KA, Kimiko I.   +8 more
europepmc   +1 more source

The Role of Direct-Acting Antivirals in Enhancing Quality of Life Among Individuals with Chronic Hepatitis C. [PDF]

Healthcare (Basel)
Pirlog MC, Danilescu CM, Alexandru DO, Streba CT, Rogoveanu I.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Antiviral resistance and direct-acting antiviral agents for HCV

Antiviral Therapy, 2012
Direct-acting antiviral (DAA) agents specifically target viral proteins. Two DAAs have been already been approved for the treatment of HCV infection and many more are in development. DAA treatment of HCV infection, however, leads to the selection of viral variants (produced by the error-prone HCV polymerase) that are resistant to the DAA agent in use ...
Aloia, A., Locarnini, S., Beard, M.
openaire   +3 more sources

Management of direct-acting antiviral agent failures

Journal of Hepatology, 2015
Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment registration studies, with rates of 1% to 7%, depending on the patients' baseline characteristics. In real life, failure is slightly higher, likely because of lower compliance.
Maria, Buti, Mar, Riveiro-Barciela, Rafael, Esteban   +2 more
openaire   +2 more sources

Benefits of Direct-Acting Antivirals for Hepatitis C

Annals of Internal Medicine, 2017
Emerging data show that direct-acting antivirals (DAAs) improve clinical outcomes in hepatitis C virus (HCV).
Anna S, Lok, Raymond T, Chung, Hugo E, Vargas, Arthur Y, Kim, Susanna, Naggie, William G, Powderly   +5 more
openaire   +2 more sources